Truist Securities Reiterates Buy on Revolution Medicines, Raises Price Target to $261
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsReiterationPrice Target
Truist Securities analyst Gregory Renza reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $241 to $261.
Truist Securities analyst Gregory Renza reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $241 to $261.